Filing Flows › Protalix BioTherapeutics (PLX) › Q2 2026 › vs Q2 2025
Protalix BioTherapeutics (PLX) Q2 2026 vs Q2 2025 (year over year)
Protalix BioTherapeutics's revenue rose $4.2M (+27%) from $15.7M in Q2 2025 to $19.9M in Q2 2026. The biggest changes: GOODS +$4.4M (+28%); LICENSE AND R&D SERVICES −$150K (-69%). Operating margin 23.5% against 7.5% (+16.0 pts).
Protalix BioTherapeutics, Q2 2026: revenue $19.9M (+27% year over year), operating margin 23.5%, net earnings $3.8M, operating cash flow −$10.4M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 23.5% | 7.5% | +16.0 pts |
| Net margin | 19.0% | 1.0% | +17.9 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| GOODS | $19.8M | $15.4M | $4.4M | +28% |
| LICENSE AND R&D SERVICES | $68K | $218K | −$150K | -69% |
| Revenue | $19.9M | $15.7M | $4.2M | +27% |
| Other income, net | $188K | −$511K | $699K | — |
| Operating profit | $4.7M | $1.2M | $3.5M | +299% |
| Costs & expenses | $15.2M | $14.5M | $738K | +5% |
| Pre-tax earnings | $4.9M | $661K | $4.2M | +635% |
| Cost of revenue | $7.8M | $5.9M | $1.9M | +32% |
| Research & development | $4.4M | $6.0M | −$1.6M | -27% |
| SG&A | $3.1M | $2.6M | $487K | +19% |
| Net earnings | $3.8M | $164K | $3.6M | 23× |
| Income tax | $1.1M | $497K | $586K | +118% |
| Operating cash sources | $15.0M | $6.2M | $8.8M | +142% |
| Depreciation | $406K | $360K | $46K | +13% |
| Share-based compensation | $398K | $427K | −$29K | -7% |
| Cash used in operations | $10.4M | $5.2M | $5.2M | +99% |
| Working capital & other | $15.0M | $6.2M | $8.8M | +142% |
Questions
How much did Protalix BioTherapeutics's revenue grow year over year in Q2 2026?
Protalix BioTherapeutics's revenue rose $4.2M (+27%) from $15.7M in Q2 2025 to $19.9M in Q2 2026.
What drove Protalix BioTherapeutics's revenue change in Q2 2026?
GOODS +$4.4M (+28%); LICENSE AND R&D SERVICES −$150K (-69%).